

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

EGAWA, KOHJI

Filed: March 28, 2001

CANCER CELL-SPECIFIC HLA-F ANTI-GEN AND A DIAGNOSTIC METHOD OF

CANCER BY USING THEREOF

Docket No. 31508

I hereby certify that this document is being deposited with the United States Postal Service as first class mall in an envelope addressed to the Assistant Commissioner

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT


The attached references are being filed to fulfill the duty of candor and good faith toward the Patent and Trademark Office, as required by 37 C.F.R. §1.56.

Respectfully submitted,

HOVEY, WILLIAMS, TIMMONS & COLLINS

Tracey S. Truitt Reg. No. 43,205 2405 Grand Boulevard, Suite 400 Kansas City, Missouri 64108

(816) 474-9050



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 31508

SERIAL NO.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT: EGAWA, KOHJI

(Use several sheets if necessary)

FILING DATE: March 28, 2001 GROUP:

U.S. PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER				DA	DATE NAME			CLASS SUBCLASS		FILING DATE IF APPROPRIATE		

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
								1				YES	МО
									-				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Egawa, Kohji et al.; Protection Against Metastasis by Immunization with an Allogeneic Lymphocyte Antigen; Cancer Immunol. Immunother. 41:384-388 (1995).
	Seo, Naohiro et al.; Expression of the Qa-2 ^k Phenotype Encoded by the Q5 ^k Gene on the Surface of Tumor Cells Derived from H-2 ^k Mice; <i>J. Exp. Med.</i> 175:647-654 (1992).
	Tanino, Takae et al.; Detection of Allogeneic Qa/TL and Ly Specificities on Murine Tumor Cells with IgD in Tumor-Regressor Serum; Cancer Immunology Immunotherapy 35:230-236 (1992).

EXAMINER: Initial if citation considered, whether not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.